Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz | Zendy

Ana BlasGarcía | Zendy; Miriam Polo | Zendy; Fernando Alegre | Zendy; Haryes A. Funes | Zendy; Estebán Martínez | Zendy; Nadezda Apostolova | Zendy; Juan V. Esplugues | Zendy

Open Access

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz

Author(s) -

Ana BlasGarcía,

Miriam Polo,

Fernando Alegre,

Haryes A. Funes,

Estebán Martínez,

Nadezda Apostolova,

Juan V. Esplugues

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku262

Subject(s) - darunavir , raltegravir , efavirenz , rilpivirine , mitochondrial toxicity , pharmacology , integrase inhibitor , reverse transcriptase inhibitor , biology , chemistry , reverse transcriptase , mitochondrion , virology , biochemistry , viral load , virus , antiretroviral therapy , rna , gene

Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events. Newer antiretrovirals, such as the integrase inhibitor raltegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine and the protease inhibitor darunavir, claim to have a better toxicological profile than efavirenz while producing similar levels of efficacy and virological suppression. The objective of this study was to determine the in vitro toxicological profile of these three new antiretrovirals by evaluating their effects on the mitochondrial and cellular parameters altered by efavirenz in hepatocytes and neurons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research